Patents by Inventor Arsalan S. Haqqani

Arsalan S. Haqqani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089704
    Abstract: Featured are compositions comprising humanized and engineered variants of an antibody variable domain (e.g., FC5), chimeric molecules comprising same, compositions comprising same, and uses thereof.
    Type: Application
    Filed: October 28, 2019
    Publication date: March 24, 2022
    Inventors: Benjamin A. Smith, Andreas Lehmann, Thomas O. Cameron, R. Blake Pepinsky, Dingyi Wen, Graham K. Farrington, Gopalan Raghunathan, Nels E. Pederson, Danica Stanimirovic, Traian Sulea, Arsalan S. Haqqani
  • Patent number: 10112998
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 30, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Patent number: 10106614
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 23, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Patent number: 10100117
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 16, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Publication number: 20170022277
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Application
    Filed: December 4, 2014
    Publication date: January 26, 2017
    Applicant: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Publication number: 20170015748
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Application
    Filed: December 4, 2014
    Publication date: January 19, 2017
    Applicant: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Publication number: 20170015749
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Application
    Filed: December 4, 2014
    Publication date: January 19, 2017
    Applicant: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert